May 15, 2025 8:30am EDT Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
May 13, 2025 8:30am EDT Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
Dec 03, 2024 8:00am EST Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit
Sep 16, 2024 8:00am EDT Presentation at the 2024 International HBV Meeting Highlights Antiviral Activity of EBT-107 as a Potential Anti-HBV Therapy
Sep 09, 2024 8:00am EDT Excision BioTherapeutics Announces Oral Presentation at the 2024 International HBV Meeting
Aug 14, 2024 11:54am EDT Excision BioTherapeutics Announces Publication in Molecular Therapy Methods & Clinical Development Highlighting EBT-104 for the Treatment of HSV-1 Keratitis
May 13, 2024 8:00am EDT Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B
Apr 22, 2024 4:31pm EDT Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting
Apr 22, 2024 4:30pm EDT Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting